AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ImmunityBio Inc. (IBRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.66

-0.24 (-6.15%)

At close: Feb 20, 2025, 3:59 PM

3.64

-0.55%

After-hours: Feb 20, 2025, 07:04 PM EST

undefined% (undefined)

Bid	3.62
Market Cap	2.67B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.9
PE Ratio (ttm)	-4.07
Forward PE	n/a
Analyst	Buy

Ask	3.65
Volume	5,713,798
Avg. Volume (20D)	6,093,125
Open	3.90
Previous Close	3.90
Day's Range	3.55 - 3.93
52-Week Range	2.28 - 10.53
Beta	undefined

About IBRX

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 28, 2015

Employees 672

Stock Exchange NASDAQ

Ticker Symbol IBRX

Website https://immunitybio.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 391.80% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ImmunityBio Inc. is scheduled to release its earnings on Mar 18, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+16.42%

ImmunityBio shares are trading higher after the co... Unlock content with Pro Subscription

3 weeks ago

+2.6%

ImmunityBio shares are trading higher after the company announced a collaboration with BioGene for a Phase 3 trial combining AKTIVA with Tislelizumab.

News

1 week ago · businesswire.com

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA) has validated...

3 weeks ago · businesswire.com

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Lt...

3 weeks ago · businesswire.com

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing...

1 month ago · seekingalpha.com

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but...

1 month ago · zacks.com

IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK

ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.

1 month ago · benzinga.com

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

On Wednesday, ImmunityBio, Inc. IBRX released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-s...

1 month ago · businesswire.com

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Adm...

1 month ago · businesswire.com

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin al...

2 months ago · seekingalpha.com

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio's recent $100M public offering was necessary to support ANKTIVA's commercialization and pipeline programs, despite the dilution and lower offering price of $3 per share. The company's cash...

2 months ago · seekingalpha.com

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

ImmunityBio's Anktiva shows promise with potential peak revenues of ~$900m annually, but faces significant competition and financial challenges, including a poorly timed $100m fundraising effort. Desp...

Load More News